GeoVax Labs reported a second-quarter 2026 net loss of $4,426,578 ($0.97 per share) and cash and cash equivalents of approximately $3.1 million as of June 30, 2026. The company said revenue from its prior BARDA contract ceased in 2026 following termination for convenience, and R&D and G&A expenses…
GeoVax Labs, Inc. reported results for the 2026 quarter showing no revenue and a reduced net loss versus the prior-year period as the company shifts focus to its lead vaccine and oncolytic programs.Financial Highlights¹ Reported as “Revenue from government contract”. ² Reported as “Net loss”. ³ Rep…
Net loss narrowed year-over-year as R&D and G&A expenses declined following the end of BARDA funding and a strategic shift to focus on lead vaccine and oncology programs. Cash runway extends into September 2026, but substantial doubt remains about ongoing viability without new capital.Original docu…
Q2 2026 saw continued advancement of lead vaccine and immuno-oncology programs, with a narrowed focus following the discontinuation of COVID-19 vaccine development. Net loss narrowed year-over-year, and cash position remained stable as the company prepares for a pivotal clinical trial.Original docu…
